Key result
Aromatase inhibitors are linked to reduced breast tissue and slower bone aging in Sertoli cell tumors.
Why the study?
Does aromatase inhibitor therapy improve gynecomastia, growth velocity, and bone age in prepubertal boys with large cell calcifying Sertoli cell tumors?
Case Report (n=6)
Yes
Does aromatase inhibitor therapy improve gynecomastia, growth velocity, and bone age in prepubertal boys with large cell calcifying Sertoli cell tumors?
Aromatase inhibitor therapy reduces gynecomastia and slows linear growth and bone age advancement in prepubertal boys with large cell calcifying Sertoli cell tumors, potentially avoiding the need for surgery.
CONTEXT: Large cell calcifying Sertoli cell tumors (LCCSCT) present in isolation or, especially in children, in association with Carney Complex (CNC) or Peutz-Jeghers Syndrome (PJS). These tumors overexpress aromatase (CYP19A1), which leads to increased conversion of delta-4-androstenedione to estrone and testosterone to estradiol. Prepubertal boys may present with growth acceleration, advanced bone age, and gynecomastia. OBJECTIVE: To investigate the outcomes of aromatase inhibitor therapy (AIT) in prepubertal boys with LCCSCTs. DESIGN: Case series of a very rare tumor and chart review of cases treated at other institutions. SETTING: Tertiary care and referral center. PATIENTS: Six boys, five with PJS and one with CNC, were referred to the National Institutes of Health for treatment of LCCSCT. All patients had gynecomastia, testicular enlargement, and advanced bone ages, and were being treated by their referring physicians with AIT. INTERVENTIONS: Patients were treated for a total of 6-60 months on AIT. MAIN OUTCOME MEASURES: Height, breast tissue mass, and testicular size were all followed; physical examination, scrotal ultrasounds, and bone ages were obtained, and hormonal concentrations and tumor markers were measured. RESULTS: Tumor markers were negative. All patients had decreases in breast tissue while on therapy. Height percentiles declined, and predicted adult height moved closer to midparental height as bone age advancement slowed. Testicular enlargement stabilized until entry into central puberty. Only one patient required unilateral orchiectomy. CONCLUSIONS: Patients with LCCSCT benefit from AIT with reduction and/or elimination of gynecomastia and slowing of linear growth and bone age advancement. Further study of long-term outcomes and safety monitoring are needed but these preliminary data suggest that mammoplasty and/or orchiectomy may be foregone in light of the availability of medical therapy.
No takes yet. Share an insight, caveat, or question.
Crocker et al. (2014) conducted a case report in Large cell calcifying Sertoli cell tumors (LCCSCT) (n=6). Aromatase inhibitor therapy was evaluated on Height, breast tissue mass, testicular size, bone ages, hormonal concentrations, and tumor markers. Aromatase inhibitor therapy in 6 prepubertal boys with large cell calcifying Sertoli cell tumors reduced breast tissue and slowed bone age advancement over 6 to 60 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: